ASPEN'S Clinical Pipeline

Our clinical development programs encompass both an autologous neuron replacement therapy in sporadic Parkinson’s disease (ANPD001) and a gene-corrected autologous neuron replacement therapy for genetic variants that increase the risk of Parkinson’s disease (ANPD002).

Our lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson’s disease.

We are also working to develop a gene-corrected autologous neuron therapy (ANPD002) that is in the research stage and targeted towards genetic variants associated with a higher risk of developing Parkinson’s disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA).

Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson’s disease in a genomic era. Trends Genet. (2015) 31:140–9. 10.1016/j.tig.2015.01.004
Sidransky, Ellen, et al. “Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.” New England Journal of Medicine 361.17 (2009): 1651-1661

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

ASPEN’S Clinical Pipeline